JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v9i12.13268ArticleThe Predictive Value of Combined Synthetic MRI Features and PSAD for Clinically Significant Prostate Cancer https://artdesignp.com/journal/JCNR/9/12/10.26689/jcnr.v9i12.13268YangYunqi,HuYukang,XiaChunhua20259122025-12-31Objective: To investigate the diagnostic and predictive value of MRI features combined with clinical indicators for prostate cancer (PCa) and clinically significant prostate cancer (csPCa), and to establish a non-invasive combined model. Methods: A total of 36 patients with pathologically confirmed benign lesions (44 foci) and 23 patients with PCa (49 foci), including 25 foci of csPCa and 68 foci of non-csPCa, were included. SyMRI quantitative maps and clinical indicators were collected, and 224 imaging features were extracted. The intra- and inter-group correlation coefficients (ICC) for each feature were calculated using intra- and inter-group correlation analysis, and features with an ICC > 0.75 were selected as stable features that could be reproducibly extracted. Independent predictors were screened using logistic regression to construct single and combined models, and the performance was evaluated using ROC curves. Results: Age, PSAD, PD map contrast, and T2 map joint entropy were significantly higher in the PCa group compared to the benign group, while the median ADC was significantly lower (p < 0.05). The above-mentioned indicators were significantly correlated with PCa and csPCa, and the diagnostic performance of the combined model was superior to that of a single MRI or clinical model. Conclusion: MRI features combined with PSAD can effectively differentiate PCa and predict csPCa, providing a non-invasive quantitative diagnostic basis for clinical practice.

Sung H, Ferlay J, Siegel R, et al., 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3): 209–249.

Adamaki M, Zoupourlis V, 2021, Prostate Cancer Biomarkers: From Diagnosis to Prognosis and Precision-Guided Therapeutics. Pharmacol Ther, 228: 107932.

Williams I, McVey A, Perera S, et al., 2022, Modern Paradigms for Prostate Cancer Detection and Management. Med J Aust, 217(8): 424–433.

Turkbey B, Rosenkrantz A, Haider M, et al., 2019, Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol, 76(3): 340–351.

Meng T, Liu H, Zhang W, et al., 2020, Application of Integrated Magnetic Resonance Imaging Relaxation Time Quantification in the Diagnosis of Prostate Cancer. Journal of Clinical Radiology, 39(03): 605–608.

Peng T, Xiao J, Li L, et al., 2021, Can the Analysis of Multiparameter MRI and Clinical Parameters Based on Machine Learning Enhance the Diagnostic Performance for Clinically Significant Prostate Cancer. Int J Comput Assist Radiol Surg, 16(12): 2235–2249.

Urraro F, Nardone V, Reginelli A, et al., 2021, MRI Radiomics in Prostate Cancer: A Study on Reliability. Front Oncol, 11: 805137.

Gao Z, Xu X, Sun H, et al., 2024, The Diagnostic and Assessment Value of Synthetic Magnetic Resonance Imaging in Determining the Aggressiveness of Prostate Cancer. Quant Imaging Med Surg, 14(8): 5473–5489.

Arita Y, Akita H, Fujiwara H, et al., 2022, Synthetic Magnetic Resonance Imaging for Evaluating Primary Prostate Cancer: Diagnostic Potential of a Non-Contrast-Enhanced Bi-Parametric Approach Augmented with Relaxometry Measurements. Eur J Radiol Open, 9: 100403.

Trecarten S, Sunnapwar A, Clarke G, et al., 2024, Prostate MRI for Identifying Clinically Significant Prostate Cancer: Updates and Future Prospects. Adv Cancer Res, 161: 71–118.

Kurokawa G, Mori K, Sasaki H, et al., 2024, Efficacy of Magnetic Resonance Imaging/Ultrasound-Guided Targeted Biopsy in Detecting Clinically Significant Prostate Cancer. Anticancer Res, 44(02): 679–686.

Kamecki H, Tokarczyk A, Dębowska M, et al., 2025, A Straightforward Nomogram for Predicting Clinically Significant Prostate Cancer During MRI-Guided Biopsy in Patients with Mild PSA Elevation and Normal DRE. Cancers, 17(05): 753.

Wibmer A, Lefkowitz R, Lakhman Y, et al., 2022, The MRI-Detectability of Clinically Significant Prostate Cancer Is Associated with Oncologic Outcomes After Prostatectomy. Clin Genitourin Cancer, 20(04): 319–325.

Kilic M, Madendere S, Vural M, et al., 2023, The Significance of the Size and Number of Index Lesions in Diagnosing Clinically Significant Prostate Cancer in Patients with PI-RADS 4 Lesions Who Underwent In-Bore MRI-Guided Prostate Biopsy. World J Urol, 41(02): 449–454.

Frisbie J, Van Besien A, Lee A, et al., 2022, PSA Density Complements the Prostate mpMRI PI-RADS Scoring System for Risk Stratification of Clinically Significant Prostate Cancer. Prostate Cancer Prostatic Dis, 26(02): 347–352.]

Yamamoto T, Okada H, Matsunaga N, et al., 2024, Clinical Characteristics and Pathological Features of Undetectable Clinically Significant Prostate Cancer on Multiparametric Magnetic Resonance Imaging: A Single-Center Retrospective Study. J Clin Imaging Sci, 14: 20.

Szempliński S, Kamecki H, Dębowska M, et al., 2022, Predictors of Clinically Significant Prostate Cancer in Patients with PI-RADS Categories 3–5 Undergoing Magnetic Resonance Imaging–Ultrasound Fusion Biopsy of the Prostate. J Clin Med, 12(01): 156.

Tamada T, Takeuchi M, Watanabe H, et al., 2024, Differentiating Clinically Significant Prostate Cancer from Clinically Insignificant Prostate Cancer Using Qualitative and Semi-Quantitative Indices of Dynamic Contrast-Enhanced MRI. Discover Oncol, 15(01): 770.

Hassanzadeh E, Alessandrino F, Olubiyi O, et al., 2018, Comparison of Quantitative Apparent Diffusion Coefficient Parameters with Prostate Imaging Reporting and Data System V2 Assessment for Detection of Clinically Significant Peripheral Zone Prostate Cancer. Abdom Radiol, 43(05): 1237–1244.